DocGo (US:DCGO)2026-03-16 22:02Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $74.9 million, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects. Excluding these revenues, there was an 11% year-over-year increase in revenue for Q4 [24] - For the full year 2025, total revenue was $322.2 million compared to $616.6 million in 2024. Adjusted EBITDA for Q4 2025 was a loss of $11.3 million, compared to a gain of $1.1 million in Q4 2024 [27] - The adjusted gross margin for Q4 2025 was 32.5%, down from 33.5% in Q4 2024, with medical transportation segment margins improving to 32.8% from 30.1% [28] Business Line Data and Key Metrics Changes - Medical transportation services revenue increased to $50.2 million in Q4 2025 from $49.1 million in Q4 2024, driven by growth in both large and small U.S. markets [25] - Mobile Health revenue for Q4 2025 was $24.8 million, down from $71.8 million in Q4 2024, but non-migrant Mobile Health revenues increased by 47% [26] - SteadyMD generated over $8 million in revenue for the first time in Q4 2025, contributing $6.1 million to DocGo's results [10] Market Data and Key Metrics Changes - The number of patient interactions for SteadyMD exceeded 4 million in 2025, up from approximately 2.5 million in 2024, indicating strong growth in telehealth services [11] - The care gap closure program saw a 12% sequential gain in assigned lives, increasing from 1.3 million to over 1.45 million [16] Company Strategy and Development Direction - The company is focused on integrating SteadyMD into its mobile health offerings and aims to consolidate provider networks by the end of Q2 2026 [11] - DocGo is exploring strategic alternatives to maximize shareholder value, engaging an investment bank for this process [22] - The company plans to reduce cash outlay as early markets mature and become self-sustaining, targeting profitability in the second half of 2026 [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about revenue growth driven by new customer expansions and improved hiring rates, raising 2026 revenue guidance to $290 million-$310 million [9] - The adjusted EBITDA loss is expected to improve to $5 million-$10 million in 2026, down from previous projections of $15 million-$25 million [39] - Management highlighted the importance of technology and automation in driving efficiency and reducing costs while maintaining high service levels [92] Other Important Information - The company incurred significant non-cash charges due to write-downs of intangible assets and goodwill, totaling $49.5 million and $22.6 million respectively in Q4 [34] - Cash and cash equivalents at year-end were $68.3 million, down from $95.2 million, primarily due to the acquisition of SteadyMD and delays in collecting migrant-related receivables [35][36] Q&A Session Summary Question: Can you provide details on the strategic alternatives process? - Management confirmed engagement with an investment bank to maximize shareholder value but could not disclose further details at this time [43] Question: What are the components driving the increased 2026 guidance? - The increase in guidance is primarily driven by improved volumes in the Medical Transportation segment and additional upside from SteadyMD [44][46] Question: Can you quantify free cash flow pressures in 2026? - Management indicated that cash balance was lower than expected due to delays in collecting $20 million in migrant receivables, but they expect to collect all of it [54][56] Question: What is the outlook for the payer business and potential new contracts? - Management noted ongoing momentum in the payer business and the potential for additional contracts, but current guidance is based on existing contracts and staffing [63][66] Question: How should we think about EBITDA cadence throughout 2026? - Most of the adjusted EBITDA loss is expected in the first half of the year, with a turnaround to profitability anticipated in the second half [90]